Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts

F. I. Tade, W. G. Wiles, G. Lu, B. Bilir, O. Akin-Akintayo, J. S. Lee, D. Patil, W. Yu, C. Ormenisan Gherasim, B. Fei, C. S. Moreno, A. O. Osunkoya, E. J. Teoh, S. Oka, H. Okudaira, M. M. Goodman, D. M. Schuster

Research output: Contribution to journalArticlepeer-review


We investigated if previously demonstrated inhibition of fluciclovine (18F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Partial inhibition of fluciclovine uptake by BCH and MeAIB can be demonstrated in vivo similar to previous in vitro modeling.

Original languageEnglish (US)
Pages (from-to)1301-1305
Number of pages5
JournalAmino Acids
Issue number9
StatePublished - Sep 1 2018
Externally publishedYes


  • Amino acid transport
  • Axumin
  • Fluciclovine
  • PC3
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts'. Together they form a unique fingerprint.

Cite this